Wie hoch ist der Preis für AlloVir, Inc. (ALVR)

Preis für AlloVir, Inc. (ALVR) ist $9.81

Wie hoch ist die Marktkapitalisierung für AlloVir, Inc. (ALVR)

Marktkapitalisierung für AlloVir, Inc. (ALVR) ist $48.68M

AlloVir, Inc. (ALVR) KBV

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Jahr	P/B-Verhältnis	ändert
2026 (TTM)	1.68	320.88%
2024	0.40	0.00%
2023	0.00	0.00%
2022	0.00	0.00%

Jahr

P/B-Verhältnis

ändert

2026 (TTM)

1.68

320.88%

2024

0.40

0.00%

2023

0.00

0.00%

2022

0.00

0.00%

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	276.71%	US
Argenx SE ARGX.US	6.2413	270.73%	NL
CSL Limited CSL.AX	2.5054	48.82%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	120.30%	US

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land